- Switzer Report - https://switzerreport.com.au -

Stocks up again. What drug is Wall St on?

The Dow was up again (adding 1.44% overnight) but there can only be one reason for the optimism that continues to drive Wall Street and that is that the market believes there’s a Coronavirus drug solution out there and it’s not too far away. Overnight, high hopes on a treatment or vaccine have seen stocks that haven’t risen quickly (since March 23) pick up momentum when it comes to higher share prices.

This should be good for our bank stocks on Monday.

On the subject of good drug news, there have been stories all week from different countries that have implied research teams are getting close to a breakthrough. Shares in Novavax rose 31.6% after being awarded a US$1.6 billion government contract to test, manufacture and commercialise a COVID-19 vaccine.

Meanwhile, The Sunday Times newspaper reported that the UK government is closing in on a £500 million supply deal with Sanofi and GlaxoSmithKline for 60 million doses of a potential virus vaccine. Then overnight Gilead Sciences said its Remdesivir “was associated with an improvement in clinical recovery and a 62 percent reduction in the risk of mortality.”

But wait, there’s more. CNBC says “BioNTech’s CEO also told The Wall Street Journal the company’s coronavirus vaccine candidate could be ready for approval by December. The company’s US-listed shares rose 5%.”

And even a local company, Recce Pharmaceutical, which presented at our microcap conference earlier this year (I interviewed the MD in May [1]) has seen its share price spike after the CSIRO has included its products in its testings and search for a COVID-19 solution.

Recce Pharmaceuticals (RCE)

Its share price spiked 55% this week! Yep, that’s the power of drugs in a world desperately in need of a hit that will put global economic growth onto a much needed high.

For the overall local market, the S&P/ASX 200 Index fell 2.3% for the week, with China anti-Oz sentiment and Victoria’s COVID-19 crisis not helping our economic outlook, which can’t be a plus for stocks. Clearly, positive drug news has the potential to bolster our market’s performance.

The UBS economics team, who has been quite bullish on a third quarter economic recovery, has looked at the restrictions now re-enforced in the southern capital and has said they represent “…a clear risk to the third quarter recovery.”

It’s why the likes of Qantas lost 8% over the week and Flight Centre 7.1%.

In contrast, Afterpay did it again and had a huge week. And if Morgan Stanley is right, it will soon be a $101 stock!

Afterpay (APT) 5 days trade

It wasn’t a great week for banks, with CBA down 1.3% to $70.63, ANZ off 4.6% to $18.30, Westpac down 4.8% to $17.66 and NAB gave up 4.7% to $17.86.

As I suggested above, as COVID-19 vaccine news improves, it’s going to be good news for stocks that have been harmed by closures. And banks, being a part of the Government’s rescue programme, lose profits and share price growth the longer this virus infects the economy.

What I liked

What I didn’t like

Buffett is buying!

Interestingly, Warren Buffett has started to buy this week. This could be seen as a positive sign. At his March shareholders’ meeting (held online), he revealed that Berkshire Hathaway’s cash was US$137 billion. He also revealed how he had dumped his airline stocks for a loss of around US$5 billion! At the time, he wasn’t a buyer. He is now. This week, Wazza slammed US$10 billion down for Dominion Energy’s natural gas transmission and storage assets, which means his company transmits 18% of natural gas in the US, up from 8% before this deal. That’s a big bet on natural gas.

The week in review: 

On our YouTube channel this week: 

Top Stocks – how they fared:  

 

The Week Ahead: 

Australia 

Monday July 13 Tourist arrivals & departures (May)
Tuesday July 14 Household card spending
Tuesday July 14 CBA Household card spending
Tuesday July 14 NAB Business survey (June)
Tuesday July 14 Weekly payroll jobs & wages (June 27)
Tuesday July 14 Weekly consumer confidence (July 12)
Tuesday July 14 Provisional overseas travel statistics (June)
Wednesday July 15 Monthly consumer confidence (July)
Thursday July 16 Employment/unemployment (June) 

Overseas 

Monday July 13 US Monthly budget statement (June)
Tuesday July 14 China International trade (June, annual)
Tuesday July 14 US Consumer prices (June)
Tuesday July 14 US NFIB Small Business Optimism index (June)
Wednesday July 15 US Import/Export price indexes (June)
Wednesday July 15 US Industrial production (June)
Wednesday July 15 US NY Empire State manufacturing index (July)
Wednesday July 15 US Federal Reserve Beige Book
Thursday July 16 China Economic (GDP) growth (June quarter)
Thursday July 16 China Retail sales/production/investment (June)
Thursday July 16 US Retail sales (June)
Thursday July 16 US Philadelphia Fed manufacturing index (July)
Thursday July 16 US NAHB Housing market index (July)
Friday July 17 US Housing starts/building permits (June)
Friday July 17 US Consumer sentiment index (July) 

Food for thought: 

Without contrary there is no progression” – William Blake 

Stocks shorted: 

ASIC releases data daily on the major short positions in the market. These are the stocks with the highest proportion of their ordinary shares that have been sold short, which could suggest investors are expecting the price to come down. The table shows how this has changed compared to the week before.  

Chart of the week: 

Top 5 most clicked: 

Recent Switzer Reports: 

Important: This content has been prepared without taking account of the objectives, financial situation or needs of any particular individual. It does not constitute formal advice. Consider the appropriateness of the information in regards to your circumstances.